In situ assay for topoisomerase 2-mediated DNA damage
拓扑异构酶 2 介导的 DNA 损伤的原位测定
基本信息
- 批准号:10323156
- 负责人:
- 金额:$ 23.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-20 至 2023-09-19
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntineoplastic AgentsApoptosisAreaBiochemicalBiological AssayBiological ModelsBrainCell NucleusCellsCharacteristicsClinical ResearchComplexDNADNA AdductsDNA DamageDNA Double Strand BreakDNA biosynthesisDetectionDevelopmentDrug TargetingEnsureEnzymesGenetic TranscriptionGoalsHistologicHumanImaging technologyImmuneImmunohistochemistryIn SituIndividualLabelLegal patentLinkMalignant NeoplasmsMediatingMedicineMethodsModelingMolecularMolecular Biology TechniquesMolecular ProfilingMonoclonal AntibodiesNoiseNucleotidesOrganParaffin EmbeddingPathologyPatientsPatternPharmaceutical PreparationsPharmacologyPhosphotyrosineProductionRegimenReproducibilityResearchSamplingSensitivity and SpecificitySignal TransductionSpecificitySpeedSpottingsStructureSuspensionsTechniquesTechnologyTestingTherapeuticTherapeutic AgentsTissuesTopoisomeraseToxinTyrosineVisualizationWorkadductanti-cancerbasecancer cellcancer initiationcancer therapycarcinogenesiscell typecommercial applicationcostdesignds-DNAin vivoinhibitor/antagonistinnovationmolecular pathologynew technologynovelnovel anticancer drugnovel strategiespreservationpreventside effecttumortumor progressiontumorigenesisvirtual
项目摘要
In situ assay for topoisomerase 2-mediated DNA damage
Abstract
Topoisomerase 2 (Top2) is essential for DNA replication and transcription, but this enzyme
generates double-strand DNA breaks during its normal catalytic cycle. This activity of Top2 is a key
contributor to cancer initiation and progression in several tumor types. Paradoxically, amplification of
Top2 DNA damage became the basis of the most successful strategy for cancer treatment. It
produced some of the best therapeutic agents used to treat human malignancies. Virtually every form
of cancer can be treated with regimens targeting Top2. The development of novel non-toxic and
selective Top2 inhibitors became one of the prioritized targets in precision anticancer medicine.
Therefore, a technology which detects and quantifies Top2-produced DNA breaks will be broadly
important in both molecular and clinical research fields. The most advantageous method should detect
its target directly in sections of normal and cancer tissues. Such an in situ assay would enable efficient
deciphering of cancer initiation mechanisms and would enhance discovery of new Top2 anticancer
drugs. However, currently there are no in situ assays specific for Top2-mediated DNA breakage.
The goal of this project is to introduce the first in situ assay for Top2 DNA damage. The new
technology will quantitatively visualize Top2-generated DNA breaks directly in tissue sections and in
individual cells. This new ability is essential for molecular pathology studies and for the assessment of
anticancer therapies. The assay will have high commercial potential because it will offer advantages of
the new detection format, speed, specificity and cost over the current biochemical approaches. It will
use a novel molecular labeling method specific for signature Top2 breaks, which carry homodimeric
adducts linked to extruding 4-nucleotide overhangs on the 5-end of DNA.
The Specific Aims of this project are:
1. To develop and validate in the context of commercial use the first tissue section technology
specifically labeling Top2-produced DNA breaks with 5’Top2 adducts and 4-base overhangs. The
technology will use the new and original in situ 5’ tyrosine enabled labeling method. To employ model
systems with controlled production of Top2 DNA breaks to validate labeling specificity of the new
approach, and to ensure its adequate sensitivity and reliability of detection.
2. To apply the new imaging technology to fixed tissue sections. To validate the assay in the context of
commercial use in models related to cancer. To assess and verify the specific, robust, and sensitive
detection of Top2 DNA cleavage by using tissue sections with Top2 DNA breaks. To test and optimize
sensitivity, specificity and commercial applicability of the new assay.
拓扑异构酶 2 介导的 DNA 损伤的原位测定
抽象的
拓扑异构酶 2 (Top2) 对于 DNA 复制和转录至关重要,但这种酶
在其正常催化循环期间产生双链 DNA 断裂。 Top2的这个活动很关键
导致多种肿瘤类型的癌症发生和进展。矛盾的是,放大
Top2 DNA 损伤成为最成功的癌症治疗策略的基础。它
生产了一些用于治疗人类恶性肿瘤的最佳治疗药物。几乎每种形式
的癌症可以通过针对 Top2 的方案进行治疗。新型无毒、
选择性Top2抑制剂成为精准抗癌医学的优先靶点之一。
因此,检测和量化 Top2 产生的 DNA 断裂的技术将得到广泛应用。
在分子和临床研究领域都很重要。最有利的方法应该检测
它直接靶向正常组织和癌组织的切片。这种原位测定将能够有效
破译癌症起始机制并将促进新的 Top2 抗癌药物的发现
药物。然而,目前还没有专门针对 Top2 介导的 DNA 断裂的原位测定。
该项目的目标是推出首个针对 Top2 DNA 损伤的原位检测方法。新的
技术将直接在组织切片中定量可视化 Top2 生成的 DNA 断裂
单个细胞。这种新能力对于分子病理学研究和评估至关重要
抗癌疗法。该测定法将具有很高的商业潜力,因为它具有以下优点:
与当前生化方法相比,新的检测形式、速度、特异性和成本。它将
使用一种新颖的分子标记方法,专门针对带有同源二聚体的特征 Top2 断裂
与 DNA 5 端突出的 4 核苷酸突出端相连的加合物。
该项目的具体目标是:
1. 在商业用途的背景下开发和验证第一个组织切片技术
用 5'Top2 加合物和 4 碱基突出端专门标记 Top2 产生的 DNA 断裂。这
技术将使用新的、原创的原位5’酪氨酸标记方法。雇用模型
控制生产 Top2 DNA 断裂的系统,以验证新标签的特异性
方法,并保证其足够的检测灵敏度和可靠性。
2.将新的成像技术应用于固定组织切片。为了在以下背景下验证测定
在与癌症相关的模型中的商业用途。评估和验证特定的、稳健的和敏感的
使用具有 Top2 DNA 断裂的组织切片检测 Top2 DNA 切割。测试和优化
新检测方法的敏感性、特异性和商业适用性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KM Wahidur Rahman其他文献
KM Wahidur Rahman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 23.67万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 23.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 23.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 23.67万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 23.67万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 23.67万 - 项目类别:














{{item.name}}会员




